<DOC>
	<DOCNO>NCT01806324</DOCNO>
	<brief_summary>The objective study : To evaluate pharmacokinetics safety experimental combination tablet contain 20 mg atorvastatin 50 mg losartan potassium administer orally single dose healthy male subject , compare concomitant administration 20 mg atorvastatin 50 mg losartan potassium tablet .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Potential Drug Interactions Fixed-dose Combination Tablet , HL-040XC , Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Healthy male subject 19 50 year age , inclusive . 2 . Subjects weigh least 121 pound ( 55 kg ) , within ± 20 % ideal body weight ( IBW ) . IBW ( kg ) = [ height ( cm ) 100 ] x 0.9 . 3 . Subjects n't congenital chronic disease . 4 . Subjects n't clinically significant abnormality vital sign measurement , physical examination , clinical lab test , ECG test Screening . 5 . Subjects able read understand consent form . 1 . Subjects history presence hypersensitivity HMGCoA reductase inhibitor atorvastatin angiotensin receptor blocker losartan . 2 . Subjects medical history may affect absorption , distribution , metabolism , excretion study drug ( e.g. , cardiovascular , respiratory , renal , endocrinal , hematological , digestive , neurological , psychiatric disease ) . 3 . Subjects creatinine clearance &lt; 80 mL/min , calculate CockcroftGault equation : ( 140 age ) x ( Wt kg ) / ( 72 x sCr ) . 4 . Subjects severe injury surgery within 4 week prior Screening . 5 . Subjects positive drug screen . 6 . Subjects take prescription herbal drug within 1 week prior Screening . 7 . Subjects take overthe counter ( OTC ) drug , may affect study subject 's safety accord judgment investigator , Screening . 8 . Subjects take herbal drug contain St. John 's Wort drug , metabolize CYP3A4 enzyme inhibit stimulate CYP enzyme ( e.g. , itraconazole , ketoconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor , nefazodone ) within 4 week prior Screening . 9 . Subjects abnormal meal pattern may affect absorption , distribution , metabolism , excretion study drug ( e.g. , take grapefruit juice 1 L per day ) . 10 . Subjects receive investigational product within 4 week prior Screening . 11 . Subjects donate blood within 6 week prior Screening . 12 . Subjects consume alcohol 21 unit per week ( 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) ca n't accept prohibition alcohol clinical study . 13 . Subjects smoke 10 cigarette per day . 14 . Subjects low blood pressure ( systolic ≤ 100 mmHg diastolic ≤ 65 mmHg ) high blood pressure ( systolic ≥ 150 mmHg diastolic ≥ 95 mmHg ) Screening . 15 . Subjects test positive serology HBsAg , HCV Ab , HIV Ab VDRL Screening . 16 . Subjects active liver disease elevate serum transaminase level high 3 time upper limit normal . 17 . Subjects inability opinion investigator comply protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>